Dr Peter Borchmann (University Hospital of Cologne, Germany) presented the HD17 study, on behalf of the German Hodgkin Study Group (GHSG) [1]. The standard of care for early-stage HL with risk factors indicating an unfavourable prognosis (“early-stage unfavourable HL”) consists of 4 cycles of chemotherapy [2x BEACOPPescalated (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) and 2x ABVD (adriamycin, bleomycin, vinblastine, dacarbazine)] followed by 30Gy radiotherapy. However, late sequalae such as cardiovascular disease and secondary malignancies
are a matter of concern for this combined modality treatment (CMT). HD17 aimed to investigate whether radiotherapy can be omitted from the CMT for patients that respond well to chemotherapy, as determined by FDG-PET, and demonstrate the efficacy of an individualised approach to treatment.
A total of 1,100 early-stage unfavourable HL (Stage I-II, with ≥1 risk factor) patients were randomised; Arm A received 2 cycles BEACOPPescalated plus 2 cycles ABVD followed by 30Gy Involved-Field Radiotherapy irrespective of FDG-PET results after chemotherapy, and Arm B received 2 cycles BEACOPPescalated plus 2 cycles ABVD followed by 30Gy Involved-Node Radiotherapy if FDG-PET was positive after chemotherapy, or 2 cycles BEACOPPescalated plus 2 cycles ABVD with a treatment stop if FDG-PET was negative after chemotherapy. The primary endpoint of HD17 was non-inferiority of Arm B in regards of progression-free survival (PFS), and key secondary endpoints were overall survival (OS) and the rate of patients achieving a complete remission (CR/CRu) at final restaging after completion of study treatment.
The primary endpoint was met. With a median observation time of 46 months, PFS for Arm A was 97.3% (95% CI 94.5-98.7), and for Arm B was 95.1% (95% CI 92.0-97.0) demonstrating non-inferiority for the PET-stratified Arm B (difference PFS 2.2 months; P=0.12). Likewise, OS at 47 months follow-up was also the same between the arms (Arm A 98.8%, 95% CI 96.7-99.6 vs Arm B 98.4%, 95% CI 96.2-99.3).
In summary, the HD17 trial has proven that omission of radiotherapy does not result in a loss of tumour control in patients responding well to a standard chemotherapy regimen. The vast majority of early stage unfavourable HL patients can be treated with the brief and highly effective 2+2 chemotherapy alone. The overall efficacy in this trial was extremely high. At 5 years follow-up, only 2 out of 1,100 patients died from HL and a single patient died from treatment emerging adverse events. The mortality of patients with early stage unfavourable HL in the HD17 study did not differ from the normal German population. PET-guided omission of radiotherapy for patients with newly diagnosed early-stage unfavourable HL could be the new standard of care.
- Borschmann P, et al. Positron emission tomography guided omission of radiotherapy in early-stage unfavorable Hodgkin lymphoma: final results of the international, randomized phase III HD17 trial by the GHSG. EHA25 Virtual, 11-21 June 2020, Abstract S101.
Posted on
Previous Article
« Pembrolizumab improves PFS for relapsed/refractory Hodgkin lymphoma Next Article
Better outcomes adding enasidenib to azacitidine in mIDH2-AML »
« Pembrolizumab improves PFS for relapsed/refractory Hodgkin lymphoma Next Article
Better outcomes adding enasidenib to azacitidine in mIDH2-AML »
Table of Contents: EHA 2020
Featured articles
Myeloid
VIALE-A: newly diagnosed chemo-ineligible AML
DEC10-VEN superior to intensive chemotherapy in high-risk AML
Magrolimab plus azacitidine: good ORR in MDS/AML
Asciminib monotherapy in Ph+ CML: major molecular responses
CML TKI interruption: Swedish registry results
Patients with lower-risk MDS benefit from imetelstat
Better outcomes adding enasidenib to azacitidine in mIDH2-AML
Lymphoid
PET-stratification can omit radiotherapy in early-stage unfavourable Hodgkin lymphoma
Pembrolizumab improves PFS for relapsed/refractory Hodgkin lymphoma
Promising first-in-human trial of epcoritamab in B-NHL
Two trials: acalabrutinib in CLL
Zanubrutinib versus ibrutinib in Waldenström macroglobulinaemia
Deep responses in R/R CLL with venetoclax monotherapy
MRD assessment post-CAR-T predicts ALL allo-HSCT bridging
Plasma Cell Dyscrasias
Daratumumab for light-chain amyloidosis
Isatuximab triplet improves PFS in R/R MM
Initial results from CAR-T cell therapy in MM: KarMMa
Graft-Versus-Host Disease
GRAVITAS-301: improved complete aGVDH response
Ruxolitinib improves steroid-refractory aGVHD across subtypes
Benign Haematology
Paroxysmal nocturnal haemoglobinuria treatment with pegcetacoplan
Mitapivat, a pyruvate kinase-R activator, in SCD is safe with early efficacy results
SCD LentiGlobin gene therapy: new data on VOC and ACS
Paediatric Haematology
Venetoclax + navitoclax promising for R/R ALL or LL
Nivolumab/brentuximab vedotin in R/R HL: good CMR rates
Bench-to-Bedside Science from the Presidential Symposium
Microbiome predicts B-ALL predisposition
Netrin-1 regulates haematopoietic stem cells
Unrecognised role of iron in neutrophil differentiation
Related Articles
September 9, 2020
GRAVITAS-301: improved complete aGVDH response
September 9, 2020
Daratumumab for light-chain amyloidosis
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com